Rakhee Makhija is a Cardiology physician. OpenAlex indexes 29 publications with 545 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8865 Synergy Dr Ste 100
Mckinney, TX 750706521
Telephone
214-814-0091Provider last certified this registry record 10 Sept 2025.
Industry payments
30 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Terumo Medical CorporationProgram year20255 payments
- BIOTRONIK INC.Program year20253 payments
- Siemens Medical Solutions USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
100%Beta blocker28.9%Carvedilol63%Metoprolol Succinate37%Part D<11 patientsStatin22.5%Atorvastatin Calcium100%Part D≥12 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Treatment of Additional Vessels During Percutaneous Coronary Intervention for Unprotected Left Main Disease: Insights From a Large Prospective Registry
The American Journal of Cardiology
2025 - Impact of diabetes mellitus on one-year outcomes of bioresorbable versus durable polymer drug-eluting stents in patients undergoing percutaneous coronary intervention following rotational atherectomy: Results from a large prospective registry
American Heart Journal Plus Cardiology Research and Practice
2025 - Transcatheter Aortic Valve Replacement: Current Status and Future Indications
Journal of Clinical Medicine
2024 - Pericardial Decompression Syndrome: A Comprehensive Review of a Controversial Entity
International Journal of Angiology
2024 - SHOULD ADDITIONAL VESSELS BE TREATED DURING LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM A LARGE PROSPECTIVE REGISTRY
Journal of the American College of Cardiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”